Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4513757
Max Phase: Preclinical
Molecular Formula: C29H40O8
Molecular Weight: 516.63
Molecule Type: Unknown
Associated Items:
ID: ALA4513757
Max Phase: Preclinical
Molecular Formula: C29H40O8
Molecular Weight: 516.63
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C=CC(=C)CCC1(C)C(C)CC(=O)C23C(=C[C@H](OC(=O)CC(C)C)CC12)[C@@H](OC(C)=O)O[C@H]3OC(C)=O
Standard InChI: InChI=1S/C29H40O8/c1-9-17(4)10-11-28(8)18(5)13-24(32)29-22(26(34-19(6)30)37-27(29)35-20(7)31)14-21(15-23(28)29)36-25(33)12-16(2)3/h9,14,16,18,21,23,26-27H,1,4,10-13,15H2,2-3,5-8H3/t18?,21-,23?,26-,27+,28?,29?/m0/s1
Standard InChI Key: BUAVTODTPBURGQ-IMXATERVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 516.63 | Molecular Weight (Monoisotopic): 516.2723 | AlogP: 4.82 | #Rotatable Bonds: 9 |
Polar Surface Area: 105.20 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 8 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.87 | CX LogD: 4.87 |
Aromatic Rings: 0 | Heavy Atoms: 37 | QED Weighted: 0.19 | Np Likeness Score: 2.85 |
1. Cai S, Risinger AL, Petersen CL, Grkovic T, O'Keefe BR, Mooberry SL, Cichewicz RH.. (2019) Anacolosins A-F and Corymbulosins X and Y, Clerodane Diterpenes from Anacolosa clarkii Exhibiting Cytotoxicity toward Pediatric Cancer Cell Lines., 82 (4): [PMID:30830773] [10.1021/acs.jnatprod.8b01015] |
Source(1):